Clinical Trials Logo

Metabolic Diseases clinical trials

View clinical trials related to Metabolic Diseases.

Filter by:

NCT ID: NCT02329067 Completed - Clinical trials for Lipid Metabolism Disorders

The Metabolic Effect of Walnuts in Healthy Subjects

WALDI
Start date: December 2014
Phase: N/A
Study type: Interventional

The objectives of the proposed study are to assess whether the metabolic effects of walnut consumption depends on which food components the walnuts substitute (i.e. carbohydrates; saturated fatty acids) and whether it is important to consume walnuts as snacks or with meals.

NCT ID: NCT02325895 Completed - Clinical trials for Bone Diseases, Metabolic

Dried Plums for Bone Health in Older Postmenopausal Women

Start date: August 2012
Phase: N/A
Study type: Interventional

The objective of the investigators current study was to examine whether 50 g dried plum would be as effective as 100 g dried plum in reversing bone loss in osteopenic older postmenopausal women.

NCT ID: NCT02311270 Completed - Metabolic Disorders Clinical Trials

Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation

Start date: September 2014
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to learn about the effects of long term carnitine use in patients with metabolic disorders and its potential relationship to cardiovascular events.

NCT ID: NCT02305914 Recruiting - Quality of Life Clinical Trials

Follow-up Study of Complications of Acute Pancreatitis

FSCAP
Start date: November 2014
Phase: N/A
Study type: Observational

This is a follow-up study focusing on long-term complications of acute pancreatitis. The primary purposes include: 1. To assess the incidence of type 2 diabetes mellitus(2-DM),impaired glucose tolerance, metabolic abnormalities of blood lipids after acute pancreatitis. 2. To observe the possible long-term clinical outcomes after acute pancreatitis attack, which may include: chronic pancreatitis, pancreatic cancer, pancreatogenic portal hypertension, autoimmune pancreatitis et al. 3. To evaluate the long-term influence of acute lung injury(PaO2/FiO2<200,FiO2 means fraction of inspiration O2) in AP patients during ICU stay on life qualities of the patients; 4. To observe the prognosis of the local complications of acute pancreatitis(AP) patients; it might be helpful to find the most effective and targeted interventions aiming at different phases after AP attack.

NCT ID: NCT02296372 Completed - Critical Illness Clinical Trials

Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients

Start date: November 2014
Phase: N/A
Study type: Interventional

Critically ill patients are on high risk for increased serum glucose levels, leading to more comorbidity and higher mortality risk. In patients with severe sepsis and septic shock hyperglycemia is a typical finding. However the need of insulin therapy is associated with an increased risk of hypoglycemia. Newly developed technologies for continuous glucose monitoring in critically ill patients may improve glycemic control and reduce glucose variability. The investigators will perform continuous glucose monitoring in critically ill patients on ICU. Measurements will be done for a period of 72h per patient. The investigators aim is to evaluate accuracy feasibility and acceptance of these methods. To analyze accuracy sensor glucose levels will be validated due to arterial blood gas measurements with the blood gas analyzer. The investigators will investigate the influence of several factors like oedema, perspiration, BMI, body temperature, pH-value application of vasoconstrictors on accuracy and feasibility of the particular system. Furthermore Nursing staff will be given a questionnaire to identify acceptance.

NCT ID: NCT02292121 Terminated - Obesity Clinical Trials

Intestinal Permeability in Obesity

LEAKY GUT
Start date: February 24, 2014
Phase: N/A
Study type: Interventional

In rodents, obesity is associated with changes in tight junctions' structure in small intestine, which impacts intestinal permeability and results in metabolic complications. Few data exist in human. We hypothesized that intestinal permeability is altered in obese subjects in comparison to lean subjects, linked to metabolic and inflammatory status and that these alterations are modified after gastric bypass.

NCT ID: NCT02278068 Completed - Diabetes Clinical Trials

COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy

Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this research study is to collect information about a new treatment for Type 2 Diabetes Mellitus (T2DM), using a medical device called the Metabolic Neuromodulation System which is intended to help regulate blood glucose levels in patients whose (T2DM) is not well controlled despite treatment with multiple medications. The medical device delivers low-level radiofrequency energy through the wall of the blood vessel to the liver to disrupt the nerves that lead to the liver. Previous research has shown that disrupting these nerves may lead to a lowering of blood sugar levels.

NCT ID: NCT02275429 Completed - Metabolic Diseases Clinical Trials

Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal

METARUN
Start date: October 2014
Phase: N/A
Study type: Interventional

Acute consequences of ultramarathon running are still unknown as very little research has been done on the matter. The investigators will assess the consequences on the metabolism of runners in the ultramarathon Madmen's Diagonal on Reunion Island. Data from the literature suggest that runners undergo loss of zinc, copper, iron, magnesium not unlike the loss of metabolites in systemic inflammatory response syndrome. The purpose of this study is to assess the metabolic disorders (selenium, zinc, vitamins B9 and B12) in ultramarathon runners, during and up to 28 days after the Madmen's Diagonal which takes place on Reunion Island every year in October.

NCT ID: NCT02270164 Withdrawn - Clinical trials for Lipid Metabolism Disorders

The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study

Start date: October 2014
Phase: N/A
Study type: Interventional

Pycrinil® is a purified extract of the artichoke leaf. Artichoke leaf extract (ALE) has some clinical trial data suggesting benefit in the treatment of cholesterol disorders in several countries, but this effect has not been studied in a U.S. population. The investigators will give ALE or a placebo to overweight men and women with low "good" cholesterol to see if ALE increases their good cholesterol. The investigators will also make sure that ALE is safe.

NCT ID: NCT02261831 Completed - Obesity Clinical Trials

Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood

MICIMAB
Start date: February 2014
Phase: N/A
Study type: Interventional

The investigators will compare 16sRDNA profile in cases and controls in order to identify bacteria associated with metabolic diseases that reside both in intestinal crypts and in blood.